{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:23Z","timestamp":1790625323820,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Allogenic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment modality in patients with transfusion-dependent thalassemia (TDT). Over the past decade, there has been a shift towards reduced-toxicity conditioning regimens such as Treosulfan-Thiotepa-Fludarabine (TTF) due to its favorable toxicity profile, potent immunosuppression, and myeloablative effects. This study explores the outcomes of TTF-based conditioning in pediatric TDT patients undergoing allogenic HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a single-center retrospective analysis of 74 pediatric patients who underwent allogenic HSCT using the TTF conditioning regimen at our center from January 2017 to May 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median age at transplant was 6.2 years (range: 1 to 18\u00a0y) and Male: female was 1.8:1. Donor types included matched sibling donor (MSD) in 45 patients (60.8%), matched unrelated donor (MUD) in 16 (21.6%), haploidentical donor in 9 (12.2%) and matched related donor (MRD) in 4 patients (5.4%). Pesaro classes I, II, and III were seen in 24 (32.4%), 32 (43.2%), and 18 (24.3%) patients, respectively. Peripheral blood was the stem cell source in all patients. Median stem cell dose was 5.2 million\/kg (range: 4.2 to 6.5 million\/kg). Four patients (5.4%) had primary graft failure. In the remaining patients, neutrophil and platelet engraftment occurred at a median of 14 days (range: 11 to 25\u00a0d) and 18 days (range: 13 to 36\u00a0d), respectively. Mixed chimerism was observed in 10 (13.5%) patients, of whom 2 developed secondary graft failure with autologous recovery. Acute and chronic graft-versus-host disease occurred in 25 (33.7%) and 7 (9.4%) patients, respectively. Cytomegalovirus reactivation was seen in 42 patients (56.7%). Six children (8.1%) suffered from veno-occlusive disease. At a median follow-up of 45.2 months (range: 1.5 to 102\u00a0mo), 5-year overall and thalassemia-free survival were 82.2% and 77.7%, respectively. Subgroup analysis by Pesaro classification showed 5-year OS rates of 83.9% for class 1+2 and 78.6% for class 3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.28). Five-year TFS was 82% for class 1+2 and 65.5% for class 3 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.049). When comparing matched sibling and matched related donor transplants with alternate donor transplants (haploidentical and matched unrelated), the 5-year OS and TFS were significantly higher in the matched donor group (95% vs. 57.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001, and 88.3% vs. 57.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TTF conditioning with a peripheral blood stem cell graft is a well-tolerated and effective approach for allogeneic HSCT in thalassemia. It demonstrates reduced toxicity and favorable transplant outcomes, with superior results in the matched family donor setting compared with the alternate donor group, supporting its role as a promising alternative to traditional busulfan-based conditioning regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003246","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:01:05Z","timestamp":1784322065000},"page":"e292-e298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Allogenic Hematopoietic Stem Cell Transplantation in Children With Transfusion Dependent Thalassemia Using Treosulfan-Thiotepa-Fludarabine Based Conditioning"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-6546","authenticated-orcid":false,"given":"Sunisha","family":"Arora","sequence":"first","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohini","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha Rastogi","family":"Panda","sequence":"additional","affiliation":[{"name":"Hematology, Fortis Memorial and Research Institute, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinidhi","family":"Nathany","sequence":"additional","affiliation":[{"name":"Hematology, Fortis Memorial and Research Institute, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Chadha","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Batra","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder Pal","family":"Singh","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur","family":"Arora","sequence":"additional","affiliation":[{"name":"Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Hematology, Fortis Memorial and Research Institute, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Pokhriyal","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Hematology, Fortis Memorial and Research Institute, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Hematology, Fortis Memorial and Research Institute, Gurugram, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Dua","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and BMT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"R1-20260928","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20260928","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199002153220701","article-title":"Bone marrow transplantation in patients with thalassemia","volume":"322","author":"Lucarelli","year":"1990","journal-title":"N Engl J Med"},{"key":"R3-20260928","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1472-6483(10)60811-5","article-title":"Stem cell transplantation for thalassemia","volume":"10","author":"Gaziev","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"R4-20260928","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1749-6632.1998.tb10483.x","article-title":"Bone marrow transplantation in thalassemia. The experience of Pesaro","volume":"850","author":"Lucarelli","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R5-20260928","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood.V87.5.2082.2082","article-title":"Marrow transplantation for patients with thalassemia: results in class 3 patients","volume":"87","author":"Lucarelli","year":"1996","journal-title":"Blood"},{"key":"R6-20260928","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","article-title":"Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan","volume":"120","author":"Bernardo","year":"2012","journal-title":"Blood"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.blre.2007.10.001","article-title":"Advances in the allogeneic transplantation for thalassemia","volume":"22","author":"Lucarelli","year":"2008","journal-title":"Blood Rev"},{"key":"R8-20260928","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20260928","doi-asserted-by":"crossref","first-page":"104186","DOI":"10.1016\/j.transci.2025.104186","article-title":"The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomes","volume":"64","author":"Aslan Candir","year":"2025","journal-title":"Transfus Apher Sci"},{"key":"R10-20260928","doi-asserted-by":"crossref","first-page":"e2017014","DOI":"10.4084\/mjhid.2017.014","article-title":"Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease","volume":"9","author":"Marzollo","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R11-20260928","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJM199309163291204","article-title":"Marrow transplantation in patients with thalassemia responsive to iron chelation therapy","volume":"329","author":"Lucarelli","year":"1993","journal-title":"N Engl J Med"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2013-07-513473","article-title":"Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach","volume":"122","author":"Gaziev","year":"2013","journal-title":"Blood"},{"key":"R13-20260928","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13287-024-04103-6","article-title":"A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent \u03b2-thalassemia","volume":"15","author":"Yang","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"R14-20260928","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jtct.2024.09.005","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies","volume":"30","author":"Kongtim","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R16-20260928","first-page":"825","article-title":"Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20260928","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R19-20260928","doi-asserted-by":"crossref","first-page":"e61637","DOI":"10.1371\/journal.pone.0061637","article-title":"Improved clinical outcomes of high-risk \u03b2 thalassemia major patients undergoing a HLA-matched related allogeneic stem cell transplant with a treosulfan-based conditioning regimen and peripheral blood stem cell grafts","volume":"8","author":"Mathews","year":"2013","journal-title":"PLoS One"},{"key":"R20-20260928","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bbmt.2012.11.007","article-title":"Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India","volume":"19","author":"Choudhary","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20260928","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-021-04732-4","article-title":"Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major","volume":"101","author":"L\u00fcftinger","year":"2022","journal-title":"Ann Hematol"},{"issue":"Issue 2","key":"R22-20260928","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jtct.2025.01.069","article-title":"Thiotepa, treosulfan, and fludarabine conditioning for haploidentical stem cell transplant with post-transplant cyclophosphamide for thalassemia and sickle cell disease","volume":"31","author":"Yadav","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"key":"R23-20260928","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jcm11040907","article-title":"Conditioning regimens in patients with \u03b2-thalassemia who underwent hematopoietic stem cell transplantation: a scoping review","volume":"11","author":"Mulas","year":"2022","journal-title":"J Clin Med"},{"key":"R24-20260928","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12519-017-0107-5","article-title":"Hematopoietic stem cell transplantation for children with \u03b2-thalassemia major: multicenter experience in China","volume":"14","author":"Li","year":"2018","journal-title":"World J Pediatr"},{"key":"R25-20260928","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R26-20260928","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2020.01.002","article-title":"Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen","volume":"26","author":"Anurathapan","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:34Z","timestamp":1790622034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003246","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2025-10-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}